Oral formulation

Abstract

To provide an oral formulation that enables the effective expression of the effects of a plurality of active ingredients.SOLUTION: An oral formulation has following components sealed within a single pouch: a first capsule enclosing a first content that includes nicotinamide mononucleotide and pyrroloquinoline quinone and / or a salt thereof as active ingredients; a tablet including spermidine and / or resveratrol as active ingredients; and a second capsule enclosing a second content that includes quercetin as an active ingredient.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to oral formulations containing multiple active ingredients. [Background technology]

[0002] In recent years, various anti-aging ingredients have been researched in line with the extension of healthy lifespan. For example, nicotinamide mononucleotide and pyrroloquinoline quinone are being researched as ingredients that activate the sirtuin gene and promote mitochondrial activity and regeneration. Spermidine and resveratrol are being researched as ingredients that activate autophagy, which promotes cell metabolism and the selective elimination of harmful substances. Quercetin and other ingredients are being researched as ingredients that activate senolytics (senescent cell removal), which removes aged and toxic cells.

[0003] As an oral preparation containing these active ingredients, for example, a solid composition (oral preparation) containing nicotinamide mononucleotide, pomegranate extract, and resveratrol has been proposed (see Patent Document 1). In the oral preparation, nicotinamide mononucleotide, pomegranate extract, and resveratrol are mixed with an excipient, and the mixture can be formulated as a powder, granules, tablets, hard capsules (capsules), or the like. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Patent No. 7287587 Summary of the Invention [Problem to be solved by the invention]

[0005] As the anti-aging ingredient, it is preferable to take the above-mentioned mitochondrial activity and regeneration promoting ingredient, autophagy activating ingredient, and senolytics activating ingredient at once, since it can further promote anti-aging. In addition, as the dosage form of the oral preparation, tablets and capsules are more preferable than powders and granules (powders) in terms of ease of taking, and tablets are more preferable than capsules. Capsules can exert efficacy according to the active ingredient if the capsule shell disintegrates (or dissolves) in water and the contents are released. Tablets can exert efficacy according to the active ingredient if they disintegrate (or dissolve) in water.

[0006] However, among the anti-aging ingredients (active ingredients) exemplified above, when quercetin is mixed with an additive and compressed into tablets, disintegration is significantly delayed depending on the formulation, and the active ingredient tends not to be released. In addition, although nicotinamide mononucleotide and pyrroloquinoline quinone have no problem with the uniformity of the content when used alone, when they are combined, the content of pyrroloquinoline quinone varies significantly. In addition, when nicotinamide mononucleotide and pyrroloquinoline quinone are molded into one tablet together with other active ingredients, not only do the contents of these change over time in stability tests, but also the contents of the other active ingredients change over time. For this reason, it is necessary to consider formulating these nicotinamide mononucleotide and pyrroloquinoline quinone separately from the other active ingredients. If there is a significant delay in release, the active ingredient cannot dissolve in the digestive tract fluid and cannot exert the desired efficacy. In addition, if there is a significant variation in the content, the required amount cannot be taken appropriately, and the expected efficacy cannot be exerted appropriately.

[0007] The present invention has been made in view of the above circumstances, and an object of the present invention is to provide an oral preparation capable of appropriately exerting the effects of multiple active ingredients. [Means for solving the problem]

[0008] The characteristic configuration of the oral preparation of the present invention for solving the above problems is as follows: a first capsule containing a first content containing nicotinamide mononucleotide and pyrroloquinoline quinone and / or a salt thereof as active ingredients; A tablet containing spermidine and / or resveratrol as an active ingredient; a second capsule containing a second content containing quercetin as an active ingredient; are sealed in a single packaging bag.

[0009] In the oral formulation of this configuration, the active ingredients nicotinamide mononucleotide, pyrroloquinoline quinone and / or a salt thereof, spermidine and / or resveratrol, and quercetin are separated into a first capsule containing nicotinamide mononucleotide and pyrroloquinoline quinone and / or a salt thereof, a tablet containing spermidine and / or resveratrol, and a second capsule containing quercetin, so that when these are taken, the efficacy of each active ingredient can be properly exerted.

[0010] In the oral formulation according to the present invention, The content of the first content in the first capsule is 185 to 195 mg. The content of the nicotinamide mononucleotide in the first content is 35 to 45% by mass, The content of the pyrroloquinoline quinone and / or a salt thereof in the first content is preferably 3 to 7% by mass.

[0011] According to the oral preparation of this configuration, even if the content of the first content, the content of nicotinamide mononucleotide, and the content of pyrroloquinoline quinone and / or its salt are set within the above ranges, when the oral preparation is taken, the capsule shell of the first capsule is broken down by gastrointestinal fluid, and the first content (nicotinamide mononucleotide, pyrroloquinoline quinone and / or its salt) is rapidly released into the gastrointestinal tract. Therefore, the efficacy of the active ingredients (nicotinamide mononucleotide, pyrroloquinoline quinone and / or its salt) contained in the first capsule can be appropriately exerted.

[0012] In the oral formulation according to the present invention, The mass of the tablet is 395 to 405 mg; The content of the spermidine in the tablet is 30 to 40% by mass, The content of resveratrol in the tablet is preferably 20 to 30% by mass.

[0013] According to the oral preparation of this configuration, even if the tablet mass, spermidine content, and resveratrol content are set within the above ranges, when the oral preparation is taken, the tablet disintegrates due to digestive fluids, and the active ingredient (spermidine and / or resveratrol) is rapidly released into the digestive tract. Therefore, the efficacy of the active ingredient (spermidine and / or resveratrol) contained in the tablet can be appropriately exerted.

[0014] In the oral formulation according to the present invention, The content of the second content in the second capsule is 275 to 305 mg. The content of the quercetin in the second content is preferably 60 to 70% by mass.

[0015] According to the oral preparation of this configuration, even if the content of the second content and the content rate of quercetin are set within the above ranges, when the oral preparation is taken, the capsule shell of the second capsule is broken down by gastrointestinal fluid, and the second content (quercetin therein) is rapidly released into the gastrointestinal tract. Therefore, the efficacy of the active ingredient (quercetin) contained in the second capsule can be appropriately exerted.

[0016] In the oral formulation according to the present invention, The first content further contains crystalline cellulose and calcium stearate, The content of the crystalline cellulose in the first content is 40 to 50% by mass, The content of the calcium stearate in the first content is preferably 5 to 15% by mass.

[0017] According to the oral preparation of this configuration, even if the first content further contains crystalline cellulose and calcium stearate, and the content ratios of crystalline cellulose and calcium stearate are set within the above ranges, when the oral preparation is taken, the capsule shell of the first capsule is broken down by gastrointestinal fluid, and the first content (nicotinamide mononucleotide, pyrroloquinoline quinone and / or salts thereof) is rapidly released into the gastrointestinal tract. Therefore, the efficacy of the active ingredients (nicotinamide mononucleotide, pyrroloquinoline quinone and / or salts thereof) contained in the first capsule can be appropriately exerted.

[0018] In the oral formulation according to the present invention, The second content further contains crystalline cellulose and calcium stearate, The content of the crystalline cellulose in the second content is 5 to 35% by mass, The content of the calcium stearate in the second content is preferably 3 to 10% by mass.

[0019] According to the oral preparation of this configuration, the second content further contains crystalline cellulose and calcium stearate, and even if the content of crystalline cellulose and calcium stearate are set within the above ranges, when the oral preparation is taken, the capsule shell of the second capsule is broken down by gastrointestinal fluid, and the second content (quercetin therein) is quickly released into the gastrointestinal tract. Therefore, the efficacy of the active ingredient (quercetin) contained in the second capsule can be appropriately exerted.

[0020] In the oral formulation according to the present invention, The tablet further contains reduced maltose syrup, crystalline cellulose, and calcium stearate, The content of the reduced maltose syrup in the tablet is 10 to 30% by mass, The content of the crystalline cellulose in the tablet is 5 to 15% by mass, The content of the calcium stearate in the tablet is preferably 1 to 5% by mass.

[0021] According to the oral preparation of this configuration, the tablet further contains reduced maltose syrup, crystalline cellulose, and calcium stearate, and even if the contents of reduced maltose syrup, crystalline cellulose, and calcium stearate are set within the above ranges, when the oral preparation is taken, the tablet disintegrates due to digestive fluid, and the active ingredient (spermidine and / or resveratrol) is rapidly released into the digestive tract. Therefore, the efficacy of the active ingredient (spermidine and / or resveratrol) contained in the tablet can be appropriately exerted. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] As a result of intensive research by the present inventors, it was found that, among the active ingredients nicotinamide mononucleotide, pyrroloquinoline quinone and / or its salt, spermidine and / or resveratrol, and quercetin, when quercetin is mixed with an additive and compressed into tablets, depending on the formulation, disintegration is significantly delayed and the active ingredient is not released. Therefore, it was found that it is effective to include quercetin in a capsule rather than in a tablet.

[0023] In addition, nicotinamide mononucleotide and pyrroloquinoline quinone and / or its salts have no problem with the uniformity of the content when used alone, but when they are mixed (combined) in powder form and the content of pyrroloquinoline quinone and / or its salts in a sample sampled from any point is measured, it has been found that there is a significant variation. In addition, when nicotinamide mononucleotide and pyrroloquinoline quinone and / or its salts are molded into a tablet together with other active ingredients, it has been found that not only does the content of these ingredients change over time in a stability test, but also the content of the other active ingredients changes over time. For this reason, it is necessary to consider formulating these two active ingredients separately from the other active ingredients. Furthermore, if there is variation in content in the powder state as described above, tableting (further dividing the powder into smaller portions) will cause even greater variation in the content of pyrroloquinoline quinone and / or its salts, and therefore it has been found that it is more effective to incorporate nicotinamide mononucleotide, and pyrroloquinoline quinone and / or its salts in a capsule rather than in a tablet.

[0024] Furthermore, it has also been found that when producing a capsule containing nicotinamide mononucleotide and pyrroloquinoline quinone and / or a salt thereof, the procedure for mixing the powder as the enclosed content is to triturate and mix pyrroloquinoline quinone and / or a salt thereof with nicotinamide mononucleotide, then add and mix calcium stearate, and then mix with crystalline cellulose, thereby suppressing solidification and aggregation of pyrroloquinoline quinone and / or a salt thereof and obtaining a uniform mixture.

[0025] On the other hand, it was found that there is no particular problem with including the remaining active ingredients, spermidine and / or resveratrol, in tablets.

[0026] Based on these findings, the present inventors have completed the present invention.

[0027] The oral preparation of the present invention will be described below. However, the present invention is not intended to be limited to the configurations described in the embodiments described below.

[0028] [Oral formulation] The oral preparation of this embodiment comprises a first capsule, a tablet, and a second capsule sealed in one packaging bag.

[0029] <First capsule> The first capsule contains a first content containing nicotinamide mononucleotide and pyrroloquinoline quinone and / or its salt as active ingredients. Nicotinamide mononucleotide and pyrroloquinoline quinone and / or its salt function as ingredients that activate the sirtuin gene and promote mitochondrial activity and regeneration. As the nicotinamide mononucleotide, β-nicotinamide mononucleotide is preferred. As the pyrroloquinoline quinone and / or its salt, pyrroloquinoline quinone disodium salt is preferred.

[0030] It is preferable that the content of the first content in the first capsule is 185 to 195 mg, the content of nicotinamide mononucleotide in the first content is 35 to 45 mass%, and the content of pyrroloquinoline quinone and / or a salt thereof in the first content is 3 to 7 mass%.

[0031] Even if the content of the first content, the content of nicotinamide mononucleotide, and the content of pyrroloquinoline quinone and / or its salt are set within the above ranges, when the oral preparation is taken, the capsule shell of the first capsule is broken down by gastrointestinal fluid, and the first content (nicotinamide mononucleotide, pyrroloquinoline quinone and / or its salt) is rapidly released into the gastrointestinal tract. Therefore, the efficacy of the active ingredients (nicotinamide mononucleotide, pyrroloquinoline quinone and / or its salt) contained in the first capsule can be appropriately exerted.

[0032] The first content further contains crystalline cellulose (e.g., microcrystalline cellulose) and calcium stearate, and it is preferable that the content of crystalline cellulose in the first content is 40 to 45% by mass and the content of calcium stearate in the first content is 5 to 15% by mass.

[0033] Even if the first content further contains crystalline cellulose and calcium stearate, and the content of crystalline cellulose and calcium stearate is set within the above range, when the capsule shell of the first capsule is broken down by gastrointestinal fluid when the oral preparation is taken, the first content (nicotinamide mononucleotide, pyrroloquinoline quinone and / or its salt) is rapidly released into the gastrointestinal tract. Therefore, the efficacy of the active ingredients (nicotinamide mononucleotide, pyrroloquinoline quinone and / or its salt) contained in the first capsule can be appropriately exerted.

[0034] The dosage form of the first content may be a powder (a mixture of powders), a granule (a granulated product of powders), or the like, but from the viewpoint of ease of preparation, a powder is preferred.

[0035] In addition to the above-mentioned active ingredients, crystalline cellulose, and calcium stearate, the first content may appropriately contain active ingredients other than the above-mentioned active ingredients, such as ingredients that promote mitochondrial activity or regeneration, and conventionally known additives used in oral preparations.

[0036] The material of the capsule shell used for the first capsule is not particularly limited as long as it is quickly disintegrated by digestive tract fluid, and any conventionally known capsule shell can be used. The size of the capsule shell can be appropriately set depending on the content of the first content.

[0037] The first capsule can be produced according to a conventionally known production method by mixing the ingredients, granulating if necessary, and then filling the capsule shell with the mixture using a capsule filling machine.

[0038] <Tablets> The tablet contains spermidine and / or resveratrol as an active ingredient. Both spermidine and resveratrol function as activating ingredients of autophagy, which promotes cell metabolism and selectively eliminates harmful substances. As resveratrol, trans-resveratrol is preferred.

[0039] The mass of the tablet is 395 to 405 mg. When the tablet contains spermidine, the spermidine content in the tablet is preferably 30 to 40% by mass. When the tablet contains resveratrol, the resveratrol content in the tablet is preferably 20 to 30% by mass.

[0040] Even if the tablet mass, spermidine content, and resveratrol content are set within the above ranges, when the oral preparation is taken, the tablet disintegrates due to digestive fluids, and the active ingredient (spermidine and / or resveratrol) is rapidly released into the digestive tract. Therefore, the efficacy of the active ingredient (spermidine and / or resveratrol) contained in the tablet can be appropriately exerted.

[0041] The tablet further contains reduced maltose syrup, crystalline cellulose (e.g., microcrystalline cellulose), and calcium stearate, and it is preferred that the content of reduced maltose syrup in the tablet is 10 to 30% by mass, the content of crystalline cellulose in the tablet is 5 to 15% by mass, and the content of calcium stearate in the tablet is 1 to 5% by mass.

[0042] Even if the tablet further contains reduced maltose syrup, crystalline cellulose, and calcium stearate, and the contents of reduced maltose syrup, crystalline cellulose, and calcium stearate are set within the above ranges, when the oral preparation is taken, the tablet disintegrates due to gastrointestinal fluid, and the active ingredient (spermidine and / or resveratrol) is rapidly released into the gastrointestinal tract. Therefore, the efficacy of the active ingredient (spermidine and / or resveratrol) contained in the tablet can be appropriately exerted.

[0043] In addition to the above-mentioned active ingredients, reduced maltose syrup, crystalline cellulose, and calcium stearate, the tablets can be appropriately formulated with active ingredients such as autophagy activating ingredients other than the above-mentioned active ingredients, and conventionally known additives used in oral preparations.

[0044] The properties of the tablet (hardness, disintegration time, etc.) can be appropriately set so that the tablet disintegrates quickly by gastrointestinal fluids. The dimensions of the tablet can be appropriately set depending on the content of the active ingredient, the content of the additives, etc.

[0045] The tablets can be produced by mixing the ingredients and compressing the mixture into tablets using a tablet press according to a conventionally known production method.

[0046] <Second capsule> The second capsule contains a second content containing quercetin as an active ingredient, which acts as an active ingredient in senolytics, which removes aging, toxic cells.

[0047] The content of the second filling in the second capsule is preferably 275 to 305 mg, and the content of quercetin in the second filling is preferably 60 to 70% by mass.

[0048] Even if the content of the second content and the content of quercetin are set within the above ranges, when the oral preparation is taken, the capsule shell of the second capsule is broken down by gastrointestinal fluid, and the second content (the quercetin therein) is rapidly released into the gastrointestinal tract. Therefore, the efficacy of the active ingredient (quercetin) contained in the second capsule can be adequately exerted.

[0049] The second content further contains crystalline cellulose (e.g., microcrystalline cellulose) and calcium stearate, and it is preferable that the content of crystalline cellulose in the second content is 5 to 35% by mass and the content of calcium stearate in the second content is 3 to 10% by mass.

[0050] Even if the second content further contains crystalline cellulose and calcium stearate, and the content of crystalline cellulose and calcium stearate are set within the above ranges, when the capsule shell of the second capsule is broken down by gastrointestinal fluids when the oral preparation is taken, the second content (quercetin therein) is rapidly released into the gastrointestinal tract. Therefore, the efficacy of the active ingredient (quercetin) contained in the second capsule can be adequately exerted.

[0051] The dosage form of the second content may be a powder (a mixture of powders), a granule (a granulated product of powders), etc., but from the viewpoint of ease of preparation, a powder is preferred.

[0052] In addition to the above-mentioned active ingredients, crystalline cellulose, and calcium stearate, the second content may appropriately contain active ingredients such as senolytics (senescent cell removal) activating ingredients other than the above-mentioned active ingredients, and conventionally known additives used in oral preparations.

[0053] The material of the capsule shell used for the second capsule is not particularly limited as long as it is quickly disintegrated by digestive tract fluid, and any conventionally known capsule shell can be used. The size of the capsule shell can be appropriately set depending on the content of the second content.

[0054] The second capsule can be produced according to a conventionally known production method by mixing the ingredients, granulating if necessary, and then filling the capsule shells with the mixture using a capsule filling machine.

[0055] <Packaging bag> The first capsule, the tablet, and the second capsule are sealed in one packaging bag. Examples of the packaging bag include packaging bags used in conventionally known strip packaging. The raw material of the packaging bag is not particularly limited, and examples thereof include resin films such as polyethylene film and polypropylene film, and composite films formed by laminating these resin films and aluminum foil. The number of the first capsule, the tablet, and the second capsule sealed in the packaging bag is not particularly limited, and may be one capsule or one tablet or more. For example, such a number may be appropriately set according to the daily dose, the number of times of taking, etc.

[0056] <Advantages> According to the oral formulation of this embodiment, the active ingredients nicotinamide mononucleotide, pyrroloquinoline quinone and / or a salt thereof, spermidine and / or resveratrol, and quercetin are separated into a first capsule containing nicotinamide mononucleotide and pyrroloquinoline quinone and / or, a tablet containing spermidine and / or resveratrol, and a second capsule containing quercetin, so that when taken, the efficacy of each active ingredient can be properly exerted.

[0057] <Prescription Examples> Formulation examples of the first capsule, tablet, and second capsule in the oral formulation are shown in Tables 1 to 3 below, but the oral formulation of the present invention is not limited to the following formulation examples. Table 3 shows a formulation example in which grape seed extract is further blended in the second content as an activating component for senolytics (removal of senescent cells). In addition, the raw materials used in the present invention are not limited to the following products and those from the following manufacturers, and other products and manufacturers having similar functions may be used as appropriate.

[0058] (Formulation example for capsule No. 1)

[0059] [Table 1]

[0060] (Tablet formulation example)

[0061] [Table 2]

[0062] (Formulation example for the second capsule)

[0063] [Table 3] EXAMPLES

[0064] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.

[0065] [Example] (Preparation of first capsule) The first capsule was prepared according to the formula in Table 4 below. Specifically, each component was weighed to a total charge of 19 kg, sieved, and then β-NMN and bio-PQQ were mixed by stirring (PQQ was triturated and mixed with β-NMN), and then food additive Ca-St was added and mixed by stirring, and then VIVAPUR101 was added and mixed by stirring to obtain the first content. The first content was filled into #3 VP.NATURAL B / C as a capsule shell so that each capsule was 190.00 mg, thereby obtaining the first capsule.

[0066] [Table 4]

[0067] (Preparation of Tablets) Tablets were prepared according to the recipe in Table 5 below. Specifically, each component was weighed to a total charge of 40 kg, sieved, and then Elion SP, Red Wine Effect R, Amalty MR-50, and Compressel S102 were stirred and mixed, water was added, kneaded, dried, and granulated to obtain a granulated product. The granulated product was mixed with food additive Ca-St, sieved, and then compressed using a tablet press to a diameter of φ10 mm and 400.00 mg per tablet to obtain tablets (plain tablets).

[0068] [Table 5]

[0069] (Preparation of second capsule) The second capsule was prepared according to the recipe in Table 6 below. Specifically, each component was weighed out to a total charge of 44.92 kg, sieved, and then all components were stirred and mixed to obtain the second content. The second content was filled into No. 2 HPMC transparent capsules as a capsule shell so that each capsule contained 280.00 mg of the second content, thereby obtaining the second capsule.

[0070] [Table 6]

[0071] [Comparative Example] (Preparation of Tablets) Tablets were prepared according to the recipe in Table 7. Specifically, each component was weighed to give a total charge of 1 kg, and then all components were mixed and stirred, and compressed into tablets with a tablet press to give a diameter of φ10 mm and a weight of 353.87 mg per tablet, thereby obtaining tablets (plain tablets).

[0072] [Table 7]

[0073] [Stability test] For the Examples and Comparative Examples, the content of the following active ingredients in each dosage form at the start of storage, and the content of the following active ingredients in each dosage form after 3 months and 5 months of storage at 40°C and 75% RH were measured according to the following method. The content after 3 months and 5 months was converted so that the content of each active ingredient at the start of storage was 100 mass%. The results are shown in Tables 8 and 9.

[0074] <β-nicotinamide mononucleotide (NMN)> The Japan Food Inspection Foundation used high performance liquid chromatography to measure the NMN content (mass%) in the first capsule in the example, and the NMN content (mass%) in the tablet in the comparative example.

[0075] <Pyrroloquinoline quinone disodium salt (PQQ)> Mitsubishi Gas Chemical Company, Inc. used high performance liquid chromatography to measure the PQQ content (mass %) in the first capsule in the Examples, and the PQQ content (mass %) in the tablet in the Comparative Examples.

[0076] <Spermidine> In the examples and comparative examples, the spermidine content (mass%) in the tablets was measured by high performance liquid chromatography at Mitsubishi Gas Chemical Company, Inc.

[0077] <Resveratrol> In the Examples and Comparative Examples, the resveratrol content (mass%) in the tablets was measured by high performance liquid chromatography at the Japan Food Analysis Center General Incorporated Foundation.

[0078] <Quercetin> The quercetin content (% by mass) in the second capsule in the example and the quercetin content (% by mass) in the tablet in the comparative example were measured using high performance liquid chromatography at the Japan Food Analysis Center, a general incorporated foundation.

[0079] <Polyphenols (grape seed extract)> The polyphenol (grape seed extract) content (% by mass) in the second capsule in the examples and the polyphenol (grape seed extract) content (% by mass) in the tablet in the comparative examples were measured by high performance liquid chromatography at the Japan Food Analysis Center, a general incorporated foundation.

[0080] [Disintegration test] A disintegration test was carried out under the following conditions in accordance with the disintegration test method of the Japanese Pharmacopoeia. The results are shown in Tables 8 and 9. Test liquid: Water ·Temperature: 37℃±2℃ Cycles (round trip): 30 cycles / min Use a support plate

[0081] [Table 8]

[0082] [Table 9]

[0083] As shown in Table 8, in the examples, by containing NMN and PQQ in the first capsule, spermidine and resveratrol in the tablet, and quercetin in the second capsule, the active ingredients in each formulation were shown to suppress the change in content from the start under accelerated conditions of 40°C 75% RH. It was also shown that the change in content of polyphenols (grape resin extract) from the start was suppressed. In addition, the first capsule, tablet, and second capsule formulations all had a disintegration time of 30 minutes or less, and were shown to disintegrate quickly.

[0084] In contrast, as shown in Table 9, in the comparative example, by containing all the active ingredients in one tablet, it was shown that the change in the content of NMN, PQQ, spermidine, resveratrol, and quercetin from the start was not suppressed compared to the examples. It was also shown that the content of polyphenol (grape resin extract) changed significantly after 3 months and 5 months from the start. In addition, the disintegration time of the tablet exceeded 55 minutes, indicating that the disintegration time was significantly delayed compared to the examples. [Industrial Applicability]

[0085] The oral preparation of the present invention can be taken by taking at least nicotinamide mononucleotide, pyrroloquinoline quinone and / or a salt thereof, spermidine and / or resveratrol, and quercetin from one package. By taking the preparation in this manner, it is possible to promote mitochondrial activity and regeneration, activate autophagy, and activate senolytics (removal of senescent cells), thereby contributing to anti-aging.

Claims

1. a first capsule containing a first content containing nicotinamide mononucleotide and pyrroloquinoline quinone and / or a salt thereof as active ingredients; A tablet containing spermidine and / or resveratrol as an active ingredient; a second capsule containing a second content containing quercetin as an active ingredient; and sealed in a single packaging bag.

2. The content of the first content in the first capsule is 185 to 195 mg; The content of the nicotinamide mononucleotide in the first content is 35 to 45% by mass, The oral preparation according to claim 1, wherein the content of the pyrroloquinoline quinone and / or a salt thereof in the first content is 3 to 7% by mass.

3. The tablet has a mass of 395 to 405 mg; The content of the spermidine in the tablet is 30 to 40% by mass, The oral formulation according to claim 1, wherein the content of resveratrol in the tablet is 20 to 30% by mass.

4. The content of the second content in the second capsule is 275 to 305 mg; The oral preparation according to claim 1, wherein the content of the quercetin in the second content is 60 to 70% by mass.

5. The first content further contains crystalline cellulose and calcium stearate, The content of the crystalline cellulose in the first content is 40 to 45% by mass, The oral preparation according to any one of claims 1 to 4, wherein the content of calcium stearate in the first content is 5 to 15% by mass.

6. The second content further contains crystalline cellulose and calcium stearate, The content of the crystalline cellulose in the second content is 5 to 35% by mass, The oral preparation according to any one of claims 1 to 4, wherein the content of calcium stearate in the second content is 3 to 10% by mass.

7. The tablet further contains reduced maltose syrup, crystalline cellulose, and calcium stearate, The content of the reduced maltose syrup in the tablet is 10 to 30% by mass, The content of the crystalline cellulose in the tablet is 5 to 15% by mass, The oral formulation according to any one of claims 1 to 4, wherein the content of calcium stearate in the tablet is 1 to 5% by mass.

Images